1. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
- Author
-
Sabatine, Marc S., Cannon, Christopher P., Gibson, Michael, C., Ambrosio, Giuseppe, López Sendón, Jose L., Montalescot, Gilles, Theroux, Pierre, Claeys, Marc J., Cools, Frank, Hill, Karen A., Skene, Allan M., Mccabe, Carolyn H., Braunwald, Eugene, and CLARITYTIMI 28 Investigators
- Subjects
Adult ,Male ,Ticlopidine ,medicine.medical_treatment ,Coronary ,Myocardial Infarction ,Hemorrhage ,Coronary Angiography ,Electrocardiography ,Reperfusion therapy ,Drug Therapy ,Fibrinolytic Agents ,Angioplasty ,medicine ,Secondary Prevention ,Humans ,Thrombolytic Therapy ,Myocardial infarction ,cardiovascular diseases ,Angioplasty, Balloon, Coronary ,Coronary Artery Bypass ,Vascular Patency ,Aged ,Aspirin ,business.industry ,Heparin ,Medicine (all) ,ST elevation ,General Medicine ,Middle Aged ,Clopidogrel ,medicine.disease ,Anesthesia ,Drug Therapy, Combination ,Female ,Platelet Aggregation Inhibitors ,Combination ,Human medicine ,business ,Balloon ,TIMI ,Fibrinolytic agent ,medicine.drug - Abstract
Background A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and death. Methods We enrolled 3491 patients, 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo. Patients received a fibrinolytic agent, aspirin, and when appropriate, heparin (dispensed according to body weight) and were scheduled to undergo angiography 48 to 192 hours after the start of study medication. The primary efficacy end point was a composite of an occluded infarct-related artery (defined by a Thrombolysis in Myocardial Infarction flow grade of 0 or 1) on angiography or death or recurrent myocardial infarction before angiography. Results The rates of the primary efficacy end point were 21.7 percent in the placebo group and 15.0 percent in the clopidogrel group, representing an absolute reduction of 6.7 percentage points in the rate and a 36 percent reduction in the odds of the end point with clopidogrel therapy (95 percent confidence interval, 24 to 47 percent; P
- Published
- 2005